December 15, 2022
From the desk of the Editor (5 Day Gainers Report)
We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep reading to see what we just uncovered...
Profound Medical
Symbol: PROF
Recent Price: $8.985
Average Analyst Price Target: $8.99 (0.17%)
Market Cap: $186.36M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Michael Sarcone, analyst at Jefferies, reiterates coverage on Profound Medical (PROF) in the Healthcare sector with a Buy rating and a price target of $ 5.5 (1 month ago).
TipRanks.com also reports that Profound Medical currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.99 . The target pricing ranges from a high forecast of $14.99 down to a low forecast of $5.50. Profound Medical (PROF)’s last closing price was $8.985 which would put the average price target at 0.17% upside.Here are 3rd party ratings for PROF:
Recent Analyst Action: Ben Kallo, analyst at Robert W. Baird, reiterates coverage on Fluence Energy (FLNC) in the Industrial Goods sector with a Buy rating and a price target of $ 27 (1 day ago).
TipRanks.com also reports that Fluence Energy currently has 6 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $22.00 . The target pricing ranges from a high forecast of $27.00 down to a low forecast of $13.00. Fluence Energy (FLNC)’s last closing price was $21.98 which would put the average price target at 0.09% upside.Here are 3rd party ratings for FLNC:
Recent Analyst Action: Yun Zhong, analyst at BTIG, reiterates coverage on Rocket Pharmaceuticals (RCKT) in the Healthcare sector with a Buy rating and a price target of $ 35 (2 days ago).
TipRanks.com also reports that Rocket Pharmaceuticals currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $54.56 . The target pricing ranges from a high forecast of $75.00 down to a low forecast of $33.00. Rocket Pharmaceuticals (RCKT)’s last closing price was $22.88 which would put the average price target at 138.46% upside.Here are 3rd party ratings for RCKT:
Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on Biomea Fusion (BMEA) in the Healthcare sector with a Buy rating and a price target of $ 37 (10 hours ago).
TipRanks.com also reports that Biomea Fusion currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $29.50 . The target pricing ranges from a high forecast of $37.00 down to a low forecast of $22.00. Biomea Fusion (BMEA)’s last closing price was $7.219 which would put the average price target at 308.64% upside.Here are 3rd party ratings for BMEA:
Recent Analyst Action: Joanne Wuensch, analyst at Citigroup, reiterates coverage on Sight Sciences (SGHT) in the Healthcare sector with a Buy rating and a price target of $ 15 (3 days ago).
TipRanks.com also reports that Sight Sciences currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $12.33 . The target pricing ranges from a high forecast of $15.00 down to a low forecast of $11.00. Sight Sciences (SGHT)’s last closing price was $14.18 which would put the average price target at -13.05% upside.Here are 3rd party ratings for SGHT:
Recent Analyst Action: David Risinger, analyst at SVB Securities, reiterates coverage on Horizon Therapeutics (HZNP) in the Healthcare sector with a Hold rating and a price target of $ 116.5 (2 days ago).
TipRanks.com also reports that Horizon Therapeutics currently has 12 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $110.41 . The target pricing ranges from a high forecast of $140.00 down to a low forecast of $76.00. Horizon Therapeutics (HZNP)’s last closing price was $113.26 which would put the average price target at -2.52% upside.Here are 3rd party ratings for HZNP:
Recent Analyst Action: Stephen Gengaro, analyst at Stifel Nicolaus, reiterates coverage on Energy Vault Holdings (NRGV) in the Industrial Goods sector with a Buy rating and a price target of $ 9 (3 weeks ago).
TipRanks.com also reports that Energy Vault Holdings currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.33 . The target pricing ranges from a high forecast of $9.00 down to a low forecast of $3.00. Energy Vault Holdings (NRGV)’s last closing price was $3.15 which would put the average price target at 100.95% upside.Here are 3rd party ratings for NRGV:
To Your Financial Future,
The Editor, WallStreetSectors.com